Given the dominant role of RAF dimerization in the pathway reactivation of cancer cells upon RAF inhibitor treatment, a “monomer-dimer” hypothesis has been suggested to explain the majority of drug resistance cases in targeted therapy[31,157]. Here, RAF1 is linked to cancer.